AGC Biologics vs ReciBioPharm: CDMO Comparison

How does AGC Biologics compare to ReciBioPharm?

As of Oct 2026, AGC Biologics: 4 FDA inspections (including 1 NAI, 3 VAI and 0 OAI), 27 EMA/MHRA GMP certificates. Signal Score 79.9. ReciBioPharm: no FDA inspections on file, 3 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of AGC Biologics and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
1 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
27
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
2
Capacity
Available
Modalities
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Keele, UK · Sodertalje, SE
Signal Score
83/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
3
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, Lentiviral, Plasmid, mRNA

Key differences

  • AGC Biologics has more FDA inspections on record (4 vs 0) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • AGC Biologics holds 27 active EMA GMP certificates; ReciBioPharm does not appear in EudraGMDP.
  • ReciBioPharm maintains 3 MHRA / UK GMP certificates; AGC Biologics does not.

Across the cross-modality scorecard, ReciBioPharm carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: AGC Biologics vs ReciBioPharm

How does AGC Biologics compare to ReciBioPharm?

On CDMO Signal's composite Signal Score, AGC Biologics is 80/100 and ReciBioPharm is 83/100; AGC Biologics has 4 FDA inspections on record vs 0 for ReciBioPharm; European coverage is 27 active EMA+MHRA certificates for AGC Biologics vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, AGC Biologics or ReciBioPharm?

Both AGC Biologics and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 4 FDA inspections on record; ReciBioPharm has 0.

How do AGC Biologics and ReciBioPharm compare on European GMP coverage?

AGC Biologics holds 27 active EMA GMP certificates and 0 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — AGC Biologics or ReciBioPharm?

AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; ReciBioPharm is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

AGC Biologics carries a Signal Score of 80/100 and ReciBioPharm carries 83/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating AGC Biologics and ReciBioPharm for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.